Regenxbio Q2 FY26 swings to net income of $22.71 million; revenue climbs to $108.02 million
RGNX•Q2 FY26 results
Regenxbio swung to GAAP net income of $22.71 million in Q2 2026 as revenue more than doubled to $108.02 million.
Operating income was $29.26 million.
Cash position and outlook
Cash, cash equivalents and marketable securities totaled $105.5 million at June 30, 2026.
Regenxbio expects funding into Q4 2027.
Revenue and expense details
License and royalty revenue more than doubled to $103.84 million, driven by a $100 million AbbVie milestone tied to NAAVIGATE dosing.
R&D expense fell 5.74% to $56.09 million; general and administrative costs climbed 8.72% to $21.62 million. Cost of license and royalty revenues dropped to $1.04 million from $5.21 million.
